• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·8143.HK
Share

Good Fellow Healthcare Holdings Limited Stocks

HK$ 0.06Last Updated 25.06.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

HK$ 10.36M

HK$ 0.06
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Good Fellow Healthcare Holdings Limited, an investment holding entity based in Central, Hong Kong, offers a range of general hospital services both within the People's Republic of China and globally. These services feature medical and surgical inpatient care, alongside health check-ups and diagnostic examinations. As of March 31, 2022, the company oversaw two general hospitals, situated in Putain and Beijing. Furthermore, it engages in medical investment, hospital administration, and consulting management services. Established in 2001, the company rebranded to its current name in February 2019, having previously operated as Hua Xia Healthcare Holdings Limited. It functions as a subsidiary of Solar Star Global Limited.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is undervalued on EV/EBITDA, overprice

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.06.2026 07:30

"Even the iPhone won't escape this": What is Wall Street saying about Apple's price hikes?

26.06.2026 03:02

Bain has revised its forecast for luxury market growth downward. Why is it talking about a recovery in the industry?

26.06.2026 01:29

Market Split: Nasdaq Falls for the Fourth Consecutive Day Despite a Rally in Chipmakers

26.06.2026 00:48

Qualcomm will produce AI chips for Meta's data centers. Its stock soared

26.06.2026 00:13

Citigroup raised its price target for SanDisk by 23%. Its stock has already risen 860% in 2026

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026